Compass Therapeutics Presents Data Demonstrating Elimination of MHC Class I Negative Tumors in In Vivo Models at the 2024 American Association for Cancer Research (AACR) Annual Meeting
Major Histocompatibility Complex Class I negative tumors are refractory to immune-oncology therapies, including resistance to checkpoint blockers, due to the loss of the fundamental recognition of...
United States San Diego Convention Center San Diego Thomas Schuetz Danna Gifford Senior Communications
Source: marketscreener.com